<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">headache </span>
   <span class="font24">treatment </span>
   <span class="font18">PTH </span>
   <span class="font17">subjects </span>
   <span class="font17">study </span>
   <span class="font16">studies </span>
   <span class="font16">acute </span>
   <span class="font15">included </span>
   <span class="font15">n = ) </span>
   <span class="font15">preventive </span>
   <span class="font14">Headache </span>
   <span class="font14">pharmacological </span>
   <span class="font14">reported </span>
   <span class="font14">{border-style </span>
   <span class="font14">px;} </span>
   <span class="font14">#ffffff;} </span>
   <span class="font14">data </span>
   <span class="font14">mean </span>
   <span class="font13">migraine </span>
   <span class="font13">patients </span>
   <span class="font13">used </span>
   <span class="font13">injury </span>
   <span class="font13">following </span>
   <span class="font13">nerve </span>
   <span class="font13">post-traumatic </span>
   <span class="font13">prophylactic </span>
   <span class="font13">relief </span>
   <span class="font13">retrospective </span>
   <span class="font12">Pharmacological </span>
   <span class="font12">Treatment. </span>
   <span class="font12">defined </span>
   <span class="font12">frequency </span>
   <span class="font12">metoclopramide </span>
   <span class="font12">articles </span>
   <span class="font12">clinical </span>
   <span class="font12">follow-up </span>
   <span class="font12">received </span>
   <span class="font12">response </span>
   <span class="font12">children </span>
   <span class="font12">medication </span>
   <span class="font12">outcome </span>
   <span class="font12">primary </span>
   <span class="font12">review </span>
   <span class="font12">search </span>
   <span class="font12">time </span>
   <span class="font12">traumatic </span>
   <span class="font12">trials </span>
   <span class="font12">Acute </span>
   <span class="font12">Ashina </span>
   <span class="font12">blocks </span>
   <span class="font12">brain </span>
   <span class="font12">mTBI </span>
   <span class="font12">provide </span>
   <span class="font11">International </span>
   <span class="font11">addition, </span>
   <span class="font11">future </span>
   <span class="font11">px; </span>
   <span class="font11">reduction </span>
   <span class="font11">topiramate </span>
   <span class="font11">treatment. </span>
   <span class="font11">{font-family </span>
   <span class="font11">PTH. </span>
   <span class="font11">Post-traumatic </span>
   <span class="font11">RCTs </span>
   <span class="font11">Single-center, </span>
   <span class="font11">age </span>
   <span class="font11">drugs </span>
   <span class="font11">font-size </span>
   <span class="font11">inclusion </span>
   <span class="font11">patient </span>
   <span class="font11">prescribed </span>
   <span class="font11">rate) </span>
   <span class="font11">seven </span>
   <span class="font11">years </span>
   <span class="font11"> days </span>
   <span class="font11"> months </span>
   <span class="font11">GON </span>
   <span class="font11">Pain </span>
   <span class="font11">Preventive </span>
   <span class="font11">TBI </span>
   <span class="font11">Treatment </span>
   <span class="font11">criteria </span>
   <span class="font11">disability </span>
   <span class="font11">double; </span>
   <span class="font11">effect </span>
   <span class="font11">follow-up. </span>
   <span class="font11">investigated </span>
   <span class="font11">mild </span>
   <span class="font11">month </span>
   <span class="font11">number </span>
   <span class="font11">open-label </span>
   <span class="font11">pediatric </span>
   <span class="font11">percent </span>
   <span class="font11">peripheral </span>
   <span class="font11">placebo-controlled </span>
   <span class="font11">resolution </span>
   <span class="font11">sustained </span>
   <span class="font11">treatments </span>
   <span class="font11">(median </span>
   <span class="font11">./s--- </span>
   <span class="font11">Cephalalgia. </span>
   <span class="font11">Classification </span>
   <span class="font11">Follow-up </span>
   <span class="font11">abortive </span>
   <span class="font11">amitriptyline </span>
   <span class="font11">attributed </span>
   <span class="font11">based </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">conducted </span>
   <span class="font11">decrease </span>
   <span class="font11">efficacy </span>
   <span class="font11">group </span>
   <span class="font11">guidelines </span>
   <span class="font11">headaches </span>
   <span class="font11">improved </span>
   <span class="font11">intervention </span>
   <span class="font11">intravenous </span>
   <span class="font11">ketorolac </span>
   <span class="font11">lost </span>
   <span class="font11">medication. </span>
   <span class="font11">military </span>
   <span class="font11">occipital </span>
   <span class="font11">placebo </span>
   <span class="font11">prochlorperazine </span>
   <span class="font11">prospective </span>
   <span class="font11">relevant </span>
   <span class="font11">screened </span>
   <span class="font11">solid; </span>
   <span class="font11">terms </span>
   <span class="font11">therapy </span>
   <span class="font11">treated </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">(i.e. </span>
   <span class="font10">./j.-...x </span>
   <span class="font10">Disorders </span>
   <span class="font10">Headache. </span>
   <span class="font10">However, </span>
   <span class="font10">Neurol </span>
   <span class="font10">Thus, </span>
   <span class="font10">assessment </span>
   <span class="font10">baseline </span>
   <span class="font10">blocks. </span>
   <span class="font10">bold </span>
   <span class="font10">characteristics </span>
   <span class="font10">chronic </span>
   <span class="font10">cohort </span>
   <span class="font10">complete </span>
   <span class="font10">continued </span>
   <span class="font10">controlled </span>
   <span class="font10">courier; </span>
   <span class="font10">database </span>
   <span class="font10">design. </span>
   <span class="font10">did </span>
   <span class="font10">dosages </span>
   <span class="font10">dose: </span>
   <span class="font10">drug </span>
   <span class="font10">em; </span>
   <span class="font10">gabapentin </span>
   <span class="font10">head </span>
   <span class="font10">headache: </span>
   <span class="font10">high </span>
   <span class="font10">included: </span>
   <span class="font10">intake </span>
   <span class="font10">international </span>
   <span class="font10">investigator </span>
   <span class="font10">lidocaine </span>
   <span class="font10">list </span>
   <span class="font10">mTBI. </span>
   <span class="font10">measured </span>
   <span class="font10">medications </span>
   <span class="font10">pain </span>
   <span class="font10">partial </span>
   <span class="font10">patients. </span>
   <span class="font10">performed </span>
   <span class="font10">physical </span>
   <span class="font10">population </span>
   <span class="font10">present </span>
   <span class="font10">provided </span>
   <span class="font10">pt;} </span>
   <span class="font10">quality </span>
   <span class="font10">rating </span>
   <span class="font10">reduced </span>
   <span class="font10">reporting </span>
   <span class="font10">research </span>
   <span class="font10">responder </span>
   <span class="font10">scale </span>
   <span class="font10">scores </span>
   <span class="font10">secondary </span>
   <span class="font10">symptoms </span>
   <span class="font10">systematic </span>
   <span class="font10">triptans </span>
   <span class="font10">using </span>
   <span class="font10"> mg, </span>
   <span class="font10"> mg/day </span>
  </p>
 </body>
</html>
